Eli Lilly and Co announced that its drug for the treatment of moderate to severe active Crohn's disease has been approved by the USA Food and Drug Administration (FDA). Crohn's disease is an inflammatory bowel disease that can cause chronic abdominal pain. The Indianapolis-based company stated on Wednesday that its developed drug, branded as Omvoh, is now approved in the USA for the treatment of two types of inflammatory bowel disease. The drug was previously approved in October 2023 for the treatment of adult ulcerative colitis.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Overnight, the AI community in the USA began discussing DeepSeek, while shareholders are anxiously asking, "Is this shorting NVIDIA?"
Holiday Reading | With a Market Cap surpassing BYD, why has Xiaomi been successful in car manufacturing?
Holiday Reading | "Hedge Fund God" Druckenmiller's latest remarks on "Trump 2.0": discussing tariffs, inflation, AI, and still shorting US Treasury bonds, among other topics.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
礼来公司克罗恩病治疗药物获FDA批准
Eli Lilly and Co's drug for the treatment of Crohn's disease has been approved by the FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
2
Views 1851
Write a comment
2
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report